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Abstract
Among the molecular, biochemical and cellular processes that orchestrate the development of the different phenotypes of 
cardiac hypertrophy in response to physiological stimuli or pathological insults, the specific contribution of exercise training has 
recently become appreciated. Physiological cardiac hypertrophy involves complex cardiac remodeling that occurs as an adap-
tive response to static or dynamic chronic exercise, but the stimuli and molecular mechanisms underlying transduction of the 
hemodynamic overload into myocardial growth are poorly understood. This review summarizes the physiological stimuli that 
induce concentric and eccentric physiological hypertrophy, and discusses the molecular mechanisms, sarcomeric organization, 
and signaling pathway involved, also showing that the cardiac markers of pathological hypertrophy (atrial natriuretic factor, 
β-myosin heavy chain and α-skeletal actin) are not increased. There is no fibrosis and no cardiac dysfunction in eccentric or 
concentric hypertrophy induced by exercise training. Therefore, the renin-angiotensin system has been implicated as one of 
the regulatory mechanisms for the control of cardiac function and structure. Here, we show that the angiotensin II type 1 (AT1) 
receptor is locally activated in pathological and physiological cardiac hypertrophy, although with exercise training it can be 
stimulated independently of the involvement of angiotensin II. Recently, microRNAs (miRs) have been investigated as a possible 
therapeutic approach since they regulate the translation of the target mRNAs involved in cardiac hypertrophy; however, miRs 
in relation to physiological hypertrophy have not been extensively investigated. We summarize here profiling studies that have 
examined miRs in pathological and physiological cardiac hypertrophy. An understanding of physiological cardiac remodeling 
may provide a strategy to improve ventricular function in cardiac dysfunction.
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Physiological cardiac hypertrophy
The term “athlete’s heart” has been widely used to char-
acterize the changes that occur in the heart due to long-term 
physical exercise in athletes. Physical exercise can be classified 
as static or dynamic and leads to two different kinds of intermit-
tent chronic cardiac workload, which induces morphological 
changes in the heart, such as concentric and eccentric physi-
ological cardiac hypertrophy, characterized by a uniform profile 
of ventricular wall and septum growth (1-3). In the subsequent 
sections we describe the hemodynamic alterations and the 
molecular mechanisms responsible for the concentric and 
eccentric cardiac hypertrophy induced by exercise training. 
We also describe the involvement of the angiotensin II type I 
(AT1) receptor and of the microRNAs (miRs) in different forms 
of cardiac hypertrophy.
Concentric cardiac hypertrophy induced by 
resistance training 
In static or isometric physical exercise (e.g., weight lifting, 
weight and hammer throwing, wrestling and bodybuilding), 
strength is developed with little or no movement. This physical 
exercise, when chronically performed, is known as resistance 
training, which is a specialized method of conditioning designed 
to increase muscle strength and power. Both skeletal and 
cardiac muscles adapt themselves in response to this type of 
training. Resistance training results in hemodynamic altera-
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tion with marked elevation of blood pressure (BP), leading to 
pressure overload in the heart, resulting in the parallel addi-
tion of sarcomeres. This leads to a predominant increase in 
cardiomyocyte cell width and consequently to an increase in 
left ventricular wall thickness without reducing the size of the 
internal cavity in diastole, with the development of concentric left 
ventricular hypertrophy (1,2,4). The increase in wall thickness 
induced by pressure overload is mainly due to an increase in 
cardiomyocyte cross-sectional area (5) (Figure 1). 
In contrast to hypertensive conditions described above, 
when there is continuous pressure overload, the cardiovas-
cular response to this exercise model is characterized by the 
intermittent increase in BP during exercise (6,7). An increase 
of 480/350 (systolic and diastolic) BP has been shown in 
bodybuilders while performing leg press exercise (6,7). Con-
centric cardiac hypertrophy might also result from pressure 
overload observed in many pathologic conditions, such as 
hypertension (8). However, this type of hypertrophy is followed 
by diastolic and/or systolic dysfunction and a disproportionate 
increase in the thickness of the left ventricle posterior wall and 
interventricular septum (8-10). Sometimes, the physiological 
hypertrophy developed by high level strength athletes presents 
a macroscopic structure similar to pathological hypertrophy, 
which could be incorrectly interpreted as pathological. More-
over, similar adaptations are usually found in athletes who use 
anabolic steroids associated with resistance training (11). This 
has also been found when these drugs were associated with 
aerobic training in experimental animals (12).
Since it is difficult to dissociate the use of metabolic supple-
ments from the abusive use of drugs in athletes who practice 
resistance training, experimental models can be used for the 
purpose of study, and one of their major advantages is the 
ability to precisely control the environmental and food intake 
conditions of all animals. We have characterized the cardiac 
adaptation induced by resistance training (13,14) according to 
a model adapted from Tamaki et al. (15).
The left ventricular mass assessed by echocardiography 
was 8, 12, and 16% larger in the resistance-trained group 
than in the control group in the first, second and third months, 
respectively. This hypertrophy showed a similar increase in 
the interventricular septum and in the free posterior wall mass. 
There was no reduction in the end-diastolic left ventricular in-
ternal diameter during the 3-month resistance-training period 
accompanied by maintenance of ventricular function, showing 
that this stimulus leads to concentric physiological cardiac 
hypertrophy (13,14).
We have shown that in rats trained at 75% of 1 repetition 
maximum (1-RM) the left ventricle systolic pressure decreased 
13% and there was an increase in the isometric force devel-
oped by the papillary muscles of rats. The improvement in 
cardiomyocyte contractility was due to an increase in myosin 
ATPase activity and an enhanced Ca2+-influx (16). The double 
Figure 1. Effect of exercise training on cardiac hypertrophy. Physiological hypertrophy is characterized by a uniform profile of 
ventricular wall and septum growth, without fibrosis and cardiac dysfunction. Aerobic exercise training, such as long-distance 
running or swimming, is matched with an increased volume overload accompanied by cardiac chamber dilation, referred 
to as eccentric hypertrophy. This phenotype is associated with the addition of sarcomeres in series to lengthen the cardio-
myocyte and to increase the width of the cell in parallel. In contrast, resistance training, such as weight lifting and wrestling, 
results in an increased pressure overload without chamber dilation, referred to as concentric hypertrophy. This phenotype is 
associated with the addition of sarcomeres in parallel to an increase in the cross-sectional cardiac area. LV = left ventricle; 
RV = right ventricle.
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product, an index of cardiac workload, was 18% lower in the 
trained group after four weeks of resistance training (13). 
The cardiovascular adaptations observed depended on the 
training exercise and were not influenced by stress, since 
circulating catecholamine levels and adrenal gland weights 
were unchanged (13).
We have shown that none of the pathological cardiac hy-
pertrophy molecular markers, atrial natriuretic factor (ANF) or 
α-myosin heavy chain (α-MHC)-to-β-MHC ratio, were changed 
in resistance-trained rats (17). It is well known that cardiomyo-
cyte contractility depends on the expression of α- and β-MHC, 
since MHC is the major contractile protein of the heart, and is 
crucial to the efficiency of cardiac performance. The α/β-MHC 
ratio varies in response to physiological and pathological 
signaling. Studies have shown a shift from α- toward β-MHC 
composition of the adult heart under pathological conditions ac-
companied by higher expression of fetal gene reprogramming, 
which correlates with impaired cardiac performance (18). Thus, 
resistance training induces physiological concentric cardiac 
hypertrophy, and could be used as a good exercise modality to 
compare physiological and pathological concentric hypertrophy 
in biochemical, molecular and cellular analyses.
Eccentric cardiac hypertrophy induced by 
endurance training
In dynamic exercise, in which athletes perform isotonic 
exercises (e.g., swimming, cycling, and running), the main 
hemodynamic changes are increased heart rate and stroke 
volume, the two components of cardiac output. In parallel, 
an increased effectiveness of the skeletal muscle pump and 
decrements in peripheral vascular resistance increase the 
venous return to the heart. Therefore, the heart overload oc-
curs predominantly as a result of the volume, leading to the 
development of eccentric left ventricular hypertrophy (1-3). 
As shown in Figure 1, the eccentric hypertrophy induced 
by aerobic or endurance training is predominantly character-
ized by the addition of sarcomeres in series, which leads to an 
increase in myocyte cell length and consequently increases the 
cardiac mass with increased chamber volume (1-3). 
To study eccentric cardiac hypertrophy, two different aero-
bic training protocols, both lasting a total of 10 weeks, were 
performed with rats. The first, a low-intensity, long-duration 
exercise protocol, consisted of swimming sessions of 60-min 
duration, 5 days a week, for 10 weeks. The second, also con-
sisting of low-intensity, high-volume training, differed from the 
first because the animals performed the same swimming 
training protocol as described above only until the end of the 
8th week. In the 9th week, they trained twice a day and the 
training consisted of swimming sessions of 60-min duration 
with a 6-h interval between sessions. In the 10th week, they 
trained three times a day in swimming sessions of 60-min 
duration with a 4-h interval between sessions. The aim of 
increasing training frequency (second protocol) was to induce 
robust cardiac hypertrophy (19). As a result, the left ventricle 
hypertrophy observed was 13% for the first swimming training 
protocol and 27% for the second. 
In contrast to pathological cardiac hypertrophy (18), the 
eccentric physiological hypertrophy reported here was not 
associated with activation of fetal marker genes of pathological 
cardiac hypertrophy. Our results showed that the first swim-
ming training protocol did not modify the gene expression of 
ANF, skeletal α-actin or α/β-MHC, whereas the second training 
protocol significantly reduced the left ventricle levels of skeletal 
α-actin by 53% and increased the left ventricle levels of α/β-
MHC by 98% (20). α-MHC has been associated with increased 
myosin ATPase activity and enhancement of contractility, cor-
roborating the improvement of ventricular function observed 
with aerobic training (21).
Chronically performed dynamic exercise or aerobic en-
durance training induces adjustments in the cardiovascular 
system (1-3). With regard to the cardiovascular effects, resting 
bradycardia has been considered to be the hallmark of aero-
bic exercise training adaptation (12,19,22). The mechanisms 
underlying the resting bradycardia are strongly dependent on 
the exercise training mode. Resting bradycardia observed 
after aerobic training has been explained by a reduction in 
sympathetic cardiac effects, increased cardiac vagal effects, 
reduction in intrinsic heart rate, and longer atrioventricular con-
duction time (22). Medeiros et al. (22) have provided evidence 
showing that resting bradycardia induced by swimming training 
is mainly parasympathetically mediated and differs from other 
dynamic training modes. The development of resting brady-
cardia indicates that aerobic conditioning was achieved with 
the aerobic training regimens. 
Associated with resting bradycardia, the increase peak 
oxygen uptake is a well-known adaptation to long-term endur-
ance training. Recently, Steding et al. (3) showed that total heart 
volume is a strong and independent predictor of peak oxygen 
uptake or maximal work capacity. Long-term endurance training 
is associated with a balanced physiological enlargement of the 
left and right ventricles in both males and females. 
In general, in most forms of physical exercise or physical 
conditioning programs, there is a combination of dynamic and 
static components. Therefore, the physiological hypertrophy 
that normally occurs is a combination of different degrees of 
both concentric and eccentric hypertrophy, leading to mixed 
cardiac hypertrophy, as observed in triathletes (23). Based 
on this fact, experimental models can be useful to study the 
separate effects. Moreover, the degree of physiologic hyper-
trophy observed is related to the intensity and duration of the 
exercise sessions, as well as to the type of physical training 
program, and is directly related to aerobic or resistance capacity. 
Although cardiac hypertrophy induced by treadmill and swim-
ming training is commonly observed, in some cases these types 
of training have failed to induce cardiac hypertrophy (24). We 
have observed that swimming training induces robust cardiac 
hypertrophy when compared to treadmill training in rats and 
mice (19,20,22,24,25). In fact, a different cardiac adaptation 
should be expected after swimming training, since this training 
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mode differs from running training with respect to body position 
in the water, water pressure and temperature regulation. The 
literature shows a different magnitude of cardiac hypertrophy 
depending on the training protocols (24); however, few stud-
ies comparing the effect of different endurance or resistance 
training modes on cardiac hypertrophy have been conducted 
in different species.
Exercise-induced cardiac hypertrophy via 
AT1 receptor 
Considerable research efforts have been focused on the 
molecular mechanisms responsible for transducing hemody-
namic load into cardiac growth induced by exercise training. 
An elevated number of intracellular signaling pathways have 
been identified as important transducers of the physiological 
hypertrophic response in cardiomyocytes (2). Several studies 
have indicated that the local renin-angiotensin system (RAS) 
is activated by hemodynamic overload and that the AT1 re-
ceptor might play a crucial role in the development of cardiac 
hypertrophy induced by load (26,27). 
The RAS has been studied for over a century and its rel-
evance as a cardiovascular regulator has grown steadily. In 
the classical RAS pathway, angiotensin II (Ang II) binding AT1 
and AT2 receptors acts as a potent regulator of fluid volumes, 
BP and cardiovascular remodeling. Many of the responses to 
Ang II mediated by the AT1 receptor can be deleterious, such 
as sympathetic nervous system activation resulting in vaso-
constriction and increased heart rate and force of contraction 
or contractility, as well as promoting cardiac hypertrophy and 
fibrosis, while the AT2 receptor counteracts the effects of the 
AT1 receptor, representing a protective mechanism in the 
heart (26,27).
Under pathological conditions such as hypertension (8), 
myocardial infarction (9) and heart failure (10), local cardiac 
RAS levels are increased by augmented protein, angiotensino-
gen (AGT), angiotensin-converting enzyme (ACE) and Ang 
II, inducing pathological cardiac hypertrophy and left ventricle 
dysfunction. In the heart, Ang II has been shown to play a role 
in the development of cardiac fibrosis via induction of fibroblast 
proliferation and collagen disposition (26-29). In addition, Ang 
II, as a growth factor, may contribute to the development of 
smooth muscle and cardiac cell hypertrophy (26-29). In fact, 
Sadoshima et al. (28) showed that the mechanical stretch in 
vitro causes acute release of Ang II from cardiomyocytes within 
10 min, and the expression of the AGT gene after 6 h. They 
also showed that Ang II acts as an initial mediator of the stretch-
induced hypertrophic response. The role and mechanisms of 
Ang II via the AT1 receptor in cardiac hypertrophy have been 
associated with increased expression of many immediate-early 
genes (c-fos, c-jun, junB, Egr-1, and c-myc) and fetal marker 
genes of cardiac hypertrophy (ANF, skeletal α-actin, β-MHC) 
conferring a pathological phenotype (29). 
In spite of many studies, it is still unclear whether activa-
tion of the cardiac RAS in response to hemodynamic overload 
predominantly occurs in cardiomyocytes or fibroblasts or both. 
Recent evidence has indicated that cardiac Ang II levels are 
implicated in the induction of fibrosis, but Ang II is not required 
for left ventricle hypertrophy (30). Using transgenic animal mod-
els for RAS components it has been shown that accentuated 
formation of local Ang II in the heart (20- to 50-fold greater than 
the levels seen in control groups) was not responsible for the 
development of the hypertrophy observed. In the same study, 
using another type of transgenic mouse that overexpressed 
a degradation-resistant form of Ang II, the hormone levels 
reached 100-fold the normal levels and began to spill into the 
circulation. Although an increase in fibrosis was shown, hyper-
trophy continued only when an excess amount of cardiac Ang 
II entered the circulation and caused an increase in BP (30,31). 
More recently, Xiao et al. (32) reported that in mice expressing 
ACE only in the heart the increase in cardiac Ang II was not 
associated with cardiac hypertrophy, indicating that the increase 
of cardiac Ang II was not sufficient to induce hypertrophy. In 
addition, transgenic mice harboring one, two, three, or four 
copies of the ACE gene showed that the magnitude of physi-
ological cardiac hypertrophy induced by swimming training was 
not associated with different ACE levels (25). Taken together, 
these results suggest that cardiac hypertrophy induced by Ang 
II depends on an increase in BP.
In contrast, several studies have implied that animal models 
overexpressing the AT1 receptor demonstrated the induction 
of cardiac hypertrophy (33). Zou et al. (34) showed in vitro and 
in vivo that the AT1 receptor is a mechanical sensor and that it 
converts mechanical stress into a biochemical signal inducing 
left ventricle hypertrophy without the involvement of Ang II. In 
agreement, Yasuda et al. (35) showed conformation changes 
in the AT1 receptor when activated by mechanical stress 
independently of Ang II, through the anticlockwise rotation 
of transmembrane 7 domains, translating it into biochemical 
signals inside the cardiac cell. Thus, these distinct responses of 
the RAS components to hypertrophic stimuli show that the RAS 
is an important modulator of cardiac function and structure.
Large clinical trials evaluating the blockade of RAS with ACE 
inhibitors or angiotensin receptor blockers have demonstrated 
an ability to prevent progression and to induce regression 
of cardiac hypertrophy improving ventricular performance 
(36,37). Indeed, the chronic administration of an AT1 receptor 
antagonist (Losartan) resulted in the reversal of fibrosis, inhibi-
tion of the post-transcriptional synthesis of procollagen type I, 
inhibition of tissue inhibitor of metalloproteinase-1 expression 
and stimulation of collagenase activity in the left ventricle of 
spontaneously hypertensive adult rats (38), thereby reducing 
the significant and independent cardiovascular risk conferred 
by cardiac remodeling. 
In the last decade, investigations have pointed out a 
cardioprotective role played by the novel branch of the RAS. 
The recently discovered member of the RAS,  ACE2, is an 
essential regulator of heart function (38) and has been used 
as a negative indicator of cardiovascular disease (CVD) due 
to its pivotal role in Ang (1-7) formation, implicated in several 
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biological effects that are opposite to those elicited by Ang 
II, acting in anti-proliferation and vasodilator actions and 
anti-fibrosis effects (39,40). Higher cardiac Ang II levels 
were associated with genetic deletion of ACE2 in mice and 
resulted in the development of severe cardiac dysfunction 
(38). Furthermore, Ang (1-7) can reduce hypertension-
induced cardiac remodeling through a direct effect on the 
heart (39). In addition to the known effect of AT1 receptor 
blockade in hindering the action of Ang II, this intervention 
stimulates the cardiac AT2 receptor and accelerates the 
processing of Ang II by the action of ACE2, inducing vaso-
dilator and anti-fibrotic effects and conferring therapeutic 
benefits on patients with CVD (40). Moreover, the continu-
ous administration of Losartan increased cardiac ACE2, 
mRNA expression and activity, and increased cardiac Ang 
(1-7) levels. Previous findings have suggested that ACE2 
maintains the important balance between Ang II and Ang 
(1-7) levels, favoring cardiovascular homeostasis (40).
Studies have shown that exercise training attenuates 
deleterious cardiac remodeling and also preserves cardiac 
function in CVD, and that these beneficial effects may be 
due in part to the exercise training-induced attenuation of the 
RAS (10). A recent study demonstrated that aerobic exercise 
training decreased cardiac Ang II levels and ACE activity in 
a genetic model of sympathetic hyperactivity-induced heart 
failure, while it increased ACE2 expression and prevented 
exercise intolerance and ventricular dysfunction with little 
impact on cardiac remodeling (10). Taken together, these 
data provide evidence that reduced cardiac RAS explains 
at least in part the beneficial effects of exercise training 
on cardiac function. There are only limited data about the 
effects of exercise training, either associated with CVD or 
not, on cardiac RAS regulating cardiac hypertrophy. 
Interestingly, we recently showed that AT1 receptor 
blockade prevents physiological left ventricle hypertrophy 
induced by resistance training (17) and aerobic exercise 
training (19,41). These studies underscore the importance 
of a better understanding of aerobic and resistance train-
ing and the regulation of left ventricle hypertrophy by the 
RAS (Figure 2).
Figure 2. Schematic presentation of the effects of exercise training on the cardiac renin-angiotensin system (RAS). 
Aerobic and resistance training induced eccentric and concentric cardiac hypertrophy, respectively, via the angiotensin 
II type 1 (AT1) receptor, and both types of physiological cardiac hypertrophy were prevented by AT1 receptor blockade 
(Losartan). We suggest that aerobic training shifts the generation of angiotensin peptides away from angiotensin II (ANG 
II) and towards ANG (1-7), implicated in vasodilation and anti-fibrosis. In contrast, resistance training did not modify 
these cardiac RAS components. Red arrows indicate points of up-regulation, down-regulation or maintenance of RAS 
components induced by exercise training. ACE = angiotensin-converting enzyme; ACE2 = angiotensin-converting en-
zyme 2; ANG (1-7) = angiotensin (1-7); AGT = angiotensinogen; RV = right ventricle; LV = left ventricle.
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Our first study (17) focused on the role of the RAS in 
cardiac hypertrophy induced by resistance training in rats. 
We observed that AT1 receptor expression increases in 
response to training without any alterations in the other 
components of the RAS. Furthermore, treatment with 
the AT1 receptor blocker Losartan prevented this adap-
tive hypertrophy (Figure 2). Indeed, our results showed 
that physiological hypertrophy is locally regulated and 
is independent of the systemic RAS. The implications of 
these results are 2-fold: first, AT1 receptor stimulation is 
necessary for the development of cardiac hypertrophy in 
response to resistance training even in the absence of 
increased Ang II; second, the mechanical stretch due to 
resistance training increases AT1 receptor expression. 
Other cardiovascular adaptations in this animal model 
have already been described by us (13,14), as previously 
documented above. 
Nevertheless, the role of the RAS in non-pressure 
overload hypertrophy models, such as aerobic exercise 
training, has not been extensively investigated. Therefore, 
the first study demonstrating the hypertrophic response of 
the adult rat heart to chronic conditioning in the presence 
and absence of an AT1 receptor antagonist showed that 
AT1 receptor blockade did not prevent physiological car-
diac hypertrophy induced by a chronic swimming program 
(42). However, the authors treated the animals with an AT1 
receptor only twice a week, probably reducing the neces-
sary potential inhibition for cardiac hypertrophy blockade. 
In addition, another potential criticism of this study is that 
exercise-associated adaptations that reflect integrative 
cardiovascular physiology, such as an increase in peak 
oxygen consumption and a decrease in resting heart 
rate, or those that may occur in skeletal muscle, such as 
increases in muscle succinate dehydrogenase and citrate 
synthase activities, were not determined (42).
In contrast, our results with swimming training have 
shown that the treatment with Losartan prevented left ven-
tricle hypertrophy (Figure 2). Similar to resistance training, 
cardiac hypertrophy was not decreased when the systemic 
RAS was inhibited by chronic salt treatment, which suggests 
that the left ventricle hypertrophy induced by swimming 
training depends on the local RAS activity instead of the 
systemic RAS (19). This was the first report of a detailed 
study performed to investigate the participation of the local 
versus systemic RAS in cardiac hypertrophy induced by 
aerobic exercise training, since all the markers of aerobic 
exercise training were confirmed with these protocols.
Interestingly, in a recent study (41) we showed that 
cardiac AGT and Ang I levels, ACE activity and protein 
expression, as well as Ang II levels were lower in swim-
ming-trained rats, although AT1 receptor levels increased 
after training. In addition, ACE2 and Ang (1-7) levels were 
increased in the hearts of swimming-trained rats. Therefore, 
we suggested that there was an increased exercise-induced 
cardiac AT1 receptor without Ang II participating in the 
cardiac hypertrophy and that the discovery that ACE2 and 
Ang (1-7) are increased in the heart by exercise suggests 
that this non-classic cardiac RAS counteracts the clas-
sic cardiac RAS. The counterbalancing effect increases 
vasodilatation and cardiac hypertrophy in response to the 
demands of aerobic capacity for greater transport of blood 
and oxygen supply to the exercising cardiac muscle (41) 
(Figure 2). Thus, our results suggest that AT1 receptor 
activation, but not Ang II, may participate in physiological 
cardiac hypertrophy induced by both resistance and aerobic 
types of exercise training. 
The molecular signaling pathways linking aerobic and 
resistance training to physiological cardiac hypertrophy 
have not been well established. Zhai et al. (43) and other 
investigators have defined a novel signaling pathway of 
mechanical stretch, demonstrating the activation of pro-
tein kinase B (PKB or Akt) by transactivation of epidermal 
growth factor receptor (EGFR) via the AT1 receptor. Re-
cent studies have shown that Akt activation is a critical 
determinant of the intracellular signaling pathway in the 
physiological growth of the heart induced by aerobic and 
resistance training (44,45). DeBosch et al. (44) observed 
impaired protein synthesis in Akt1 knockout (Akt1-/-) 
mouse cardiomyocytes after insulin-like growth factor 
1 (IGF-1) stimulation. In addition, the authors showed 
that cardiac hypertrophy assessed by measurement of 
the left ventricle weight/tibial length ratio, cardiomyocyte 
cross-sectional area, and cardiac function assessed by 
transthoracic echocardiography were significantly impaired 
in Akt1-/- swimming-trained mice in 90-min sessions twice 
daily for 20 days when compared with congenic sedentary 
controls, indicating that Akt1 is required for physiological 
cardiac hypertrophy (44). In contrast, pathological cardiac 
hypertrophy did not activate the Akt signal cascade and in 
some cases the absence of Akt1 profoundly exacerbated 
the transverse aortic constriction or endothelin 1-stimulated 
pathological cardiac hypertrophic, suggesting that the Akt 
activation pathway may differentiate between physiological 
and pathological hypertrophy (44,45). 
Accordingly, we observed that the swimming training 
protocols increased the cardiac phosphoSer473-Akt protein 
expression, indicating its participation in physiological 
cardiac hypertrophy (20). Therefore, in a recent study we 
showed that a session of strength exercise consisting of 4 
sets of 12 repetitions with an 80% work overload promoted 
increased Akt activity in a group exercised and killed 30 
min after the strength training session. This increased Akt 
activity was also accompanied by an increase in phos-
phorylation of mammalian target of rapamycin (mTOR). 
Interestingly, these effects were blocked by Losartan 
treatment in the exercised groups, suggesting activation 
of the AT1 receptor-Akt-mTOR signaling pathway after the 
resistance exercise session - a potential mechanism for 
cardiac hypertrophy (46). 
Although a large number of studies have shown that 
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Akt is cardioprotective, others using transgenic mice with 
cardiac-specific expression of activated Akt have demon-
strated that chronic Akt activation has detrimental effects 
after ischemia/reperfusion injury, due to feedback inhibition 
of phosphoinositide 3-kinase (PI3K) activity through both 
proteasome-dependent degradation of insulin receptor 
substrate-1 (IRS-1) and inhibition of transcription of IRS-1 
and IRS-2. This mechanistic connection is demonstrated by 
the rescue of function and reduced injury seen after resto-
ration of PI3K signaling. Thus, the authors demonstrated 
that PI3K-dependent but Akt-independent pathways are 
crucial for full cardioprotection and suggest a mechanism 
by which chronic Akt activation may become maladaptive 
(47). A possible explanation for the apparent controversial 
results of the literature could be the origin of Akt activa-
tion, since the models being considered are undoubtedly 
different, one being an exercise training model and the 
other represented by transgenic mice with exacerbated 
Akt activation. This would imply, at least in part, distinct 
effects of Akt-driven cardiac hypertrophy signaling since 
exercise-induced stress would be an intermittent stimulus, 
while it would be continuous and in transgenic mice.
Among the molecular processes that control cardiac 
hypertrophy in response to physiological or pathological 
stimuli, the contribution of miRs has recently become ap-
preciated. Recent studies have shown the development 
of miR-regulated pathological cardiac hypertrophy (48). 
In addition, miRs may be important for normal develop-
ment and for physiological cardiac hypertrophy induced by 
exercise training, at least in part, regulating target genes 
that contribute to physiological left ventricle hypertrophy, 
such as the cardiac RAS genes. 
MicroRNAs can be tiny modulators of 
cardiac hypertrophy induced by exercise 
training
MiRs are short, single-stranded RNAs that have few 
nucleotides (17-22), and work as “brakes” for many cellular 
processes, since they regulate the protein expression of 
target genes. The mechanism of action of an miR is called 
post-transcriptional, i.e., these molecules are coupled with 
partial complementarity in regions 3’ untranslated mRNA 
targets, inhibiting the translation of the mRNA into a pro-
tein. Several miR genes cluster into families based on 
their sequence similarity, especially to the region covering 
nucleotides 2-8 of the 5’ portion called the “seed region”, 
in which the base pairing between the miR and its mRNA 
is perfectly complementary. It is considered that miRs 
with identical seed regions may target the same sets of 
genes (48).
The biogenesis of miRs is accomplished through 
sequential enzymatic reactions: RNA polymerase II tran-
scribes primary miR (pri-miR) that receives the action of 
two RNase III endonucleases: the first called DROSHA, 
that cleaves pri-miR into pre-miR, and the second in the 
cytoplasm, called DICER, that generates a duplex con-
taining mature miRs, ready to exert the suppression of 
translation initiation, where the RNA-induced silencing 
complex (RISC) component prevents the binding of eIF-4E, 
a translation factor in the 7-methylguanosine cap region 
of a targeted mRNA (49).
Several in vivo and in vitro studies have shown that 
miRs regulate a myriad of cellular processes, including 
heart development and cardiac hypertrophy, both under 
physiological and pathological conditions (50-53). Some 
important issues have been highlighted regarding the 
participation of miR in the process of pathological cardiac 
hypertrophy, since many targets can be regulated simul-
taneously or synergistically by one or more miRs, and 
miRs also can be regulated by molecular bases involved 
in cardiac hypertrophy and other processes, reinforcing 
or attenuating its phenotype (53-55). A recent review 
outlined some functional concepts about the action of 
miRs on their targets, which may be intronic for multiple 
targets, by functional cooperativity as well as physiological 
buffering (56).
Evidence has shown a signature pattern of miRs that 
are up-regulated or down-regulated in pathological car-
diac hypertrophy: miR-1, miR-29, miR-30, miR-133, and 
miR-150 frequently are down-regulated, while miR-21, 
miR-23a, miR-125, miR-195, miR-199, and miR-214 are 
up-regulated. Nevertheless, there has been little investi-
gation about miRs and physiological cardiac hypertrophy 
(51,57).
The miR family more firmly established as a regulator 
of cardiac hypertrophy, and which is highly expressed in 
the heart, undoubtedly comprises the miR-1, 133a and 
133b family. The in vitro overexpression of miR-133 and 
miR-1 inhibited cardiac hypertrophy (50). In contrast, 
suppression of this miR-133 induced pronounced cardiac 
hypertrophy. Additionally, the cited study showed that both 
miR-1 and miR-133 were down-regulated in three models 
of cardiac hypertrophy: transverse aortic constriction, Akt 
transgenic mice and high-intensity interval training and 
physiological concentric cardiac hypertrophy. The main 
target genes that were validated were the Ras homo-
logue gene family-A (Rhoa), cell division control protein 
42 (Cdc42) and Wolf-Hirschhorn syndrome candidate 2 
(NELFA protein/WHSC2), which play a role in a general 
program of hypertrophy and are valid both for physiological 
and pathological cardiac hypertrophy (50).
We have investigated whether the physiological eccen-
tric cardiac hypertrophy induced by two different swimming 
training protocols described above could induce a similar 
expression profile for these miRs. We showed that the 
expression of miR-1, 133a and 133b was similar to the 
expression in pathological and concentric cardiac hyper-
trophy. Additionally, miR-1, 133a and 133b are similarly 
down-regulated in both aerobically trained groups related 
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to sedentary animals, also showing a common pattern of 
expression that suggests an involvement in general pro-
grams for cardiac hypertrophy (Figure 3) (20). However, 
there is an unanswered question about whether other 
miRs are differentially expressed in physiological cardiac 
hypertrophy when compared to the pathological type and 
thus further investigation is necessary to delineate and dif-
ferentiate the expression of miRs in concentric and eccentric 
cardiac physiological hypertrophy (Figure 4).
Another in vitro study with isoproterenol and aldosterone 
treatment showed that miR-23 also is a pro-hypertrophic 
miR, and that under pressure overload its expression was 
shown to be up-regulated by the transcription nuclear fac-
tor of activated T-cells 3 (NFATc3) that directly activates 
miR-23a expression through the transcriptional machinery. 
In turn, muscle ring-finger protein-1 (MuRF1) is a target of 
miR-23, since its protein level and MuRF1-3’UTR were both 
suppressed in a dose-dependent manner with constructs of 
miR-23a. Knockdown of miR-23a could attenuate cardiac 
hypertrophy, suggesting that miR-23a is able to convey the 
hypertrophic signal (52). 
Moreover, the overexpression of miR-195, considered 
a stress-inducible miR, in transgenic mice resulted in dra-
matic pathological cardiac remodeling and heart failure, 
showing that miR-195 alone was sufficient to drive cardiac 
hypertrophy. MiR-195 initially induced cardiac growth that 
progressed to a dilated phenotype (57).
In a study using mice and surgery with aortic banding, 
miR-21 was increased by more than 4-fold when compared 
with the sham surgical group. Similar aberrant expression 
of the most up-regulated miR, miR-21, was also found in 
cultured neonatal hypertrophic cardiomyocytes stimulated 
with Ang II or phenylephrine. Modulation of miR-21 ex-
pression via antisense-mediated depletion (knockdown) 
had a significant negative effect on cardiac hypertrophy 
and up-regulation of miR-21 expression-induced cardiac 
hypertrophy. The targets that have already been validated 
are mitogen-activated protein kinase (MAPK), FasLigand 
(FasL), phosphatase tensin homolog deleted on chromo-
some 10 (PTEN), which stimulate the Akt pathway. Recently, 
antagonist results were observed in miR experiments on 
animals. Reports have suggested that an miR-21 antagomir 
might be therapeutically useful in preventing heart failure in 
mice, although genetic deletion of miR-21 did not confer a 
dysfunctional phenotype, suggesting possible confounding 
factors that may be a product of technical variations, miR 
redundancy or nonspecific effects of a cholesterol-modified 
antagomir (54,55).
The miR-29 family has also been validated as a regulator 
of gene expression of collagen I, collagen III and fibrillin I, 
and is involved in pathological cardiac hypertrophy and in 
heart failure processes. The down-regulation of miR-29 in 
vitro and in vivo using a mouse myocardial infarction model 
enhanced the fibrotic response and expression of collagens, 
whereas overexpression of miR-29 in fibroblasts reduced 
collagen expression (53). Recently, we showed that rats 
subjected to two swimming training protocols with moderate- 
and high-volume training presented physiological cardiac 
hypertrophy and increased gene expression of miR-29, 
which were linear with the increase in training volume. The 
miR-29 up-regulation was accompanied by improvement 
in ventricular compliance and was closely correlated with 
the decrease in gene and protein expression of collagens 
I and III. These data suggest that increased expression 
of miR-29 plays an important protective role in the control 
of cardiac collagen and hypertrophy induced by aerobic 
training (Figure 4) (20).
The miR-208 is called “MyomiR” due to the fact that it 
is one among others (miR-499 and miR-206) exclusively 
expressed in muscle tissues. MiR-208 is expressed by intron 
27 of the α-MHC and is in the top hierarchy of regulatory 
steps since it controls Myh7b or β-MHC gene expression. 
MiR-208 targets several genes that are transcriptional re-
pressors of the β-MHC gene and also activates slow fiber 
gene expression. These targets were validated by compari-
son of the expression of corresponding proteins in heart 
extracts from wild and knockout mice for miR-208, and by 
the generation of transgenic mice that overexpress this miR 
and extinguish β-MHC gene expression or protein, suggest-
ing that this miR leads to a network of miRs that regulate 
the pattern of fiber and muscle performance (58).
Although the RAS plays a critical role in regulating 
physiological and pathological processes in the cardio-
vascular system, very few of the predicted sites have been 
experimentally validated. The mouse miR-143/145 cluster, 
Figure 3. Effect of exercise training on relative expression of car-
diac miR-1, miR-133a and miR-133b analyzed by real-time PCR. 
miR = microRNA; S = sedentary Wistar rats; T1 = rats trained by 
swimming sessions for 10 weeks, 60 min per session, 5 days per 
week; T2 = similar to T1 until the end of the 8th week; in the 9th 
week rats swam two sessions per day and in the 10th week they 
swam three sessions per day. *P < 0.01 compared to S rats (one-
way ANOVA and Tukey post hoc test). N = 5 animals/group. Data 
are reported as means ± SD. miR = microRNA.
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that has exclusive expression in heart and smooth muscle 
cells during development, is required for acquisition of the 
contractile phenotype by vascular smooth muscle cells 
(VSMCs) and plays a role in the regulation of BP. VSMCs 
from miR-143/145 knockout animals presented incapaci-
tated contractile abilities, favored neointimal lesion devel-
opment, and protein overexpression of membrane-bound 
ACE. Pharmacological inhibition of either ACE or the AT1 
receptor partially reversed vascular dysfunction and normal-
ized gene expression in miR-143/145-deficient mice. These 
results may offer a new approach to vascular repair and to 
the attenuation of arteriosclerotic pathogenesis (59).
Another study has also shown that miR-155 specifically 
targets a predicted site of the AT1 receptor. Experiments 
involving transfection of cells that mimic mature miR-155 
showed that this miR inhibited the expression of human AT1 
receptor and also attenuated Ang II-induced signaling via 
the AT1 receptor in fibroblasts and VSMCs. Other experi-
ments with antimir have demonstrated that transfection of 
anti-miR-155 increased AT1 receptor expression and also 
Figure 4. The regulation of miRs by aerobic training controls phenotypes that contribute to physiological cardiac hypertro-
phy. Aerobic exercise training is a powerful stimulus modulating several miRs that regulate their target mRNAs, thereby 
contributing to the phenotype of physiological cardiac hypertrophy through different signaling pathways. Red arrows indi-
cate points of up-regulation or down-regulation of miRs, proteins and cardiac function induced by exercise training. Rhoa 
= Ras homologue gene family-A; CDC42 = cell division control protein 42; NELFA protein/WHSC2 = Wolf-Hirschhorn 
syndrome candidate 2; COLI and COLIII = collagens I and III; ACE and ACE 2 = angiotensin-converting enzymes 1 and 
2; miR = microRNA.
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enhanced Ang II signaling via this receptor (60).
Despite the fact that the literature has presented studies 
discussing the relationship of miRs and cardiac hypertrophy 
in cardiovascular disease and phenotypes, it is important to 
emphasize that, to our knowledge, only one study involv-
ing cardiac hypertrophy induced by physical training and 
miRs has been published, and the differential expression 
between the types of cardiac hypertrophy (physiological vs 
pathological) has not been explored. The training protocol 
adopted was high-intensity training that promoted concentric 
cardiac hypertrophy, whereas aerobic training promotes 
eccentric cardiac hypertrophy (2,50). We showed the role 
of the miRs and their relation with RAS in physiological left 
ventricular hypertrophy showing biochemical and molecular 
mechanisms. The exercise training decreased miR-143 that 
could up-regulate cardioprotective genes such as ACE2, 
and also increased miRNA-27 that could down-regulate 
cardiac ACE expression. Together these effects might 
provide the additional aerobic capacity required by the 
exercised heart (41).
Since exercise training has beneficial effects on the 
cardiovascular system, the investigation of the miRs dif-
ferentially expressed in concentric and eccentric cardiac 
hypertrophy induced by exercise training can contribute to 
selecting miRs and establishing a strategy for silencing or 
overexpressing specific miRs in the therapeutic treatment 
of cardiac diseases. 
In conclusion, most studies in the literature, comparing 
pathological to physiological cardiac hypertrophy, refer to 
hypertrophy induced by aerobic physical training. However, 
it is relevant to show that the concentric cardiac hypertro-
phy induced by resistance training is also physiological. 
Both concentric and eccentric cardiac hypertrophy can be 
induced by physiological (intermittent) and pathological 
cardiac overload. The patterns of gene and protein expres-
sion are induced by different cardiac stimuli or stresses, 
promoting different forms of cardiac hypertrophy and 
signaling transduction pathways. The recent class of RNA 
discovered, miRs, may help to understand the molecular 
mechanisms responsible for mediating the different forms 
of cardiac hypertrophy. Since exercise training promotes 
benefits to the cardiovascular system as a whole, delineat-
ing the molecular mechanisms involved in concentric and 
eccentric cardiac hypertrophy promoted by exercise train-
ing may contribute to the development of new therapeutic 
and non-pharmacological treatment to improve ventricular 
function in pathological conditions.
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